Drug Profile
TAK 243
Alternative Names: AOB-87172; MLN-7243; TAK-243Latest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Millennium
- Developer Takeda Oncology
- Class Antineoplastics; Cyclopentanes; Organic sulfur compounds; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action NF-kappa B inhibitors; Ubiquitin-protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Lymphoma
Most Recent Events
- 25 Jan 2024 National Cancer Institute plans a phase I trial for Solid tumours and Lymphoma (Late-stage disease, Metastatic-disease, Second-line therapy or greater) (IV) in April 2024 (NCT06223542)
- 14 Apr 2023 Preclinical trials in Lymphoma in USA (Intratumoural)
- 14 Apr 2023 Pharmacodynamics data from a preclinical studies in Lymphoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)